Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Gossamer Bio (GOSS) EBIAT (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of EBIAT data on record, last reported at -$48.2 million in Q3 2025.

  • For Q3 2025, EBIAT fell 56.55% year-over-year to -$48.2 million; the TTM value through Sep 2025 reached -$156.2 million, down 117.96%, while the annual FY2024 figure was -$56.5 million, 68.56% up from the prior year.
  • EBIAT reached -$48.2 million in Q3 2025 per GOSS's latest filing, down from -$38.3 million in the prior quarter.
  • Across five years, EBIAT topped out at $49.2 million in Q2 2024 and bottomed at -$59.4 million in Q3 2022.
  • Average EBIAT over 4 years is -$39.3 million, with a median of -$42.5 million recorded in 2023.
  • Peak YoY movement for EBIAT: surged 215.85% in 2024, then tumbled 177.74% in 2025.
  • A 4-year view of EBIAT shows it stood at -$55.8 million in 2022, then rose by 13.66% to -$48.1 million in 2023, then skyrocketed by 31.4% to -$33.0 million in 2024, then plummeted by 46.0% to -$48.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBIAT were -$48.2 million in Q3 2025, -$38.3 million in Q2 2025, and -$36.6 million in Q1 2025.